[Robert: paste actual Google Review quote — filtered to mention this page's topic]
[Robert: First name + initial]
[Robert: month year of review]
A doctor-led overview of the seven GLP-1 weight-loss medications transforming obesity care — Mounjaro, Zepbound, Wegovy, Ozempic, Saxenda, Liraglutide, and the investigational Retatrutide. Compare mechanism, peer-reviewed efficacy, dosing, side-effect profiles, and real Thai-clinic cost. Choose the right path with Dr. Kenika.
Treatments supervised by Dr. Kenika Norrachetdecha
Medical Director · Thai License #72509
● Mon–Sat 8 AM–6 PM · Online consults daily · Reply in 2 Min
Personal consultation included with every program
That's −17.8 kg — you'd weigh .
Based on the 20.9% trial-mean. Individual outcomes vary.GLP-1 receptor agonists are a class of medications that mimic the gut hormone glucagon-like peptide-1. By binding to the body's own GLP-1 receptors, they slow gastric emptying, reduce appetite signalling in the brain, and lower blood sugar through glucose-dependent insulin release.
The class was originally developed for type 2 diabetes — exenatide was the first approved in 2005. Weight-loss applications followed over the next two decades as trials repeatedly showed substantial, durable weight reduction as a secondary effect.
Today the class includes daily and weekly options, single-agonist (GLP-1 only) and dual-agonist (GIP + GLP-1) molecules, and next-generation triple-agonist agents like retatrutide in late-stage trials.
A single GLP-1 receptor binding event triggers three separate downstream effects, each of which contributes to weight loss and glycemic control.
GLP-1 binding in the hypothalamus reduces ghrelin signalling and increases satiety. Patients describe a quieter "food noise" and earlier fullness during meals.
Slowed gastric emptying prolongs the sensation of fullness after meals and reduces post-prandial glucose spikes. This effect attenuates over time as the body adapts.
Glucose-dependent insulin secretion improves glycemic control without provoking hypoglycemia in non-diabetic patients. This is why the same molecules treat both obesity and T2D.
Mounjaro, Wegovy, Ozempic, and Saxenda are the four GLP-1 medications TRT Bangkok prescribes. Each fits a different patient profile.
Peak weight-loss values are mean reductions reported in pivotal phase-3 trials. Individual results vary; see each medication's dedicated page for full data.
From the first exenatide approval in 2005 to current dual- and triple-agonist agents in trials, the class has evolved in steady increments.
No framework replaces the doctor consultation, but these three questions narrow the choice quickly and frame the conversation with Dr. Kenika.
Pure weight loss → Wegovy or Mounjaro. Glycemic control with weight loss → Ozempic or Mounjaro. Both, with the strongest efficacy → Mounjaro (dual GIP + GLP-1 mechanism).
Highly sensitive or first GLP-1 → Saxenda (gentler daily titration). Average tolerance → Wegovy with slow escalation. Comfortable with stronger GI signal during titration → Mounjaro at lower starting dose.
Maximum mean reduction → Mounjaro at 15 mg (−20.9% in SURMOUNT-1). Strong but well-established → Wegovy at 2.4 mg (−14.9% in STEP-1). Gentlest entry point → Saxenda.
Pick your treatment, enter your weights, see your trajectory. All data from peer-reviewed clinical trials. Individual outcomes vary — final program plan determined in private consultation.
Your trajectory · based on clinical-trial mean
Estimator data drawn from NEJM-published Phase 3 trials (SURMOUNT-1 Jastreboff 2022, STEP-1 Wilding 2021, SCALE Pi-Sunyer 2015) and Phase 2 retatrutide data (NEJM Jastreboff/Kaplan 2023). Individual outcomes vary by adherence, baseline BMI, comorbidities, diet, and resistance training. Final medication choice and dose plan determined in private consultation with Dr. Kenika.
Each program is personalized based on your profile, medical history, and goals.
Step 1 of 5
Step 2 of 5
Select all that apply, or "None of these"
Step 3 of 5
Confidential — only your doctor sees this
Step 4 of 5
Step 5 of 5
Dr. Kenika's recommendation for you
Your access
—
Our actual clinic · Real photos
Authentic medications. Direct access to Dr. Kenika. Comprehensive metabolic care beyond GLP-1 alone.
Authentic Medications
Mounjaro, Zepbound (Eli Lilly), Wegovy, Ozempic, Saxenda (Novo Nordisk) — all sourced through the licensed Thai pharmaceutical supply chain.
Direct Doctor Access
WhatsApp Dr. Kenika directly. Every GLP-1 prescription personally supervised by the Medical Director.
Beyond GLP-1
Multi-modal metabolic care: GLP-1 plus hormone optimization, IV recovery, and advanced peptide protocols.
In Thailand for treatment? Our Pattaya walk-in clinic offers same-day GLP-1 consultations, on-site lab work, and your first injection — no appointment needed.
In published Phase-3 obesity trials, tirzepatide (Zepbound / Mounjaro) at 15 mg weekly produced 20.9% mean body-weight loss at 72 weeks (SURMOUNT-1). Investigational retatrutide showed 24.2% in a Phase-2 trial at 48 weeks. Wegovy (semaglutide 2.4 mg) produced 14.9% at 68 weeks (STEP-1).
Same active ingredient (tirzepatide), same dosing, same manufacturer (Eli Lilly). The only difference is FDA-approved indication: Mounjaro for type 2 diabetes, Zepbound for chronic weight management. Pharmacologically identical.
Both are weekly semaglutide injections from Novo Nordisk. Wegovy reaches a higher maintenance dose (2.4 mg) and is FDA-approved for chronic weight management. Ozempic tops out at 2 mg and is FDA-approved for type 2 diabetes.
Obesity is a chronic condition. STEP-4 trial data showed patients who stopped semaglutide regained approximately two-thirds of lost weight within one year. Current evidence supports long-term treatment.
Liraglutide has been studied over a decade; semaglutide nearly as long. The SELECT trial (2023) demonstrated cardiovascular benefit over 5 years of treatment, supporting long-term safety in adults with obesity and established cardiovascular disease.
Ozempic and Mounjaro are FDA-approved for type 2 diabetes only. When prescribed for weight loss in non-diabetic patients, this is off-label. The active molecule is identical to the obesity-approved versions (Mounjaro = Zepbound; Ozempic ≈ Wegovy at lower dose).
For weekly medications (Wegovy, Ozempic, Mounjaro, Zepbound): if you remember within 5 days, take the missed dose. If more than 5 days, skip and resume your usual day. For daily Saxenda: don't double-dose — resume next day.
Some lean-mass loss is expected — trials report 25–40% of total weight from lean tissue. Adequate protein (1.2–1.6 g per kg body weight) and resistance training protect muscle. Our doctor-led program includes a muscle-preservation protocol.
Licensed
Thai Pharmacy
Pharmaceutical
Grade
Doctor
Supervised
Same-Day
Care
Real reviews from real patients on Google Business Profile. Currently 5.0 ★ from 15 verified reviews — and growing. Reviews are updated regularly.
[Robert: paste actual Google Review quote — filtered to mention this page's topic]
[Robert: paste actual Google Review quote — filtered to mention this page's topic]
[Robert: paste actual Google Review quote — filtered to mention this page's topic]
Peer-reviewed primary sources, FDA prescribing information, and manufacturer documentation.
Additional clinical questions are discussed during your private consultation with Dr. Kenika.
Direct access to Dr. Kenika. Authentic medications. Three access points across Thailand.
Personal medical supervision · Cancel anytime · Authentic medications from Eli Lilly and Novo Nordisk
Book via WhatsApp · Free eligibility check
Each GLP-1 protocol has a different mechanism, trial profile, and outcome ceiling. Compare or explore by location.
Eli Lilly's dual GIP/GLP-1 agonist. Highest trial-mean of any approved GLP-1. Best fit for goals above 15%.
See program →
Novo Nordisk's most-prescribed GLP-1. Excellent track record for goals up to 15%. Built-in outcome estimator.
See program →
Investigational GLP-1/GIP/Glucagon triple agonist. Highest documented mean reduction. Private-consultation program.
See program →
In-person consultation, baseline labs, and same-week start. Walk-in or appointment. Most international patients begin here.
See clinic →